GLPG2737, a CFTR Inhibitor, Prevents Cyst Growth in Preclinical Models of Autosomal Dominant Polycystic Kidney Disease.

Am J Nephrol · 2025 · PMC12140590 · PMID 40300563

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Unlike the P18 study, GLPG2737, tolvaptan, or their combination yielded various outcomes depending on the readout: GLPG2737 improved projected cyst volume, LnTKV, and BUN, but only showed a trend toward the reduction of fibrosis, cAMP, and KW/BW.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.